Client News

Roquefort Therapeutics plc: Update on Acquisition of Oncogeni Limited and Placing
Home / Client News / Roquefort Therapeutics plc: Update on Acquisition of Oncogeni Limited and Placing

Roquefort Therapeutics (LSE:ROQ), the Main Market listed biotech company focused on early-stage opportunities in the biotechnology sector, is pleased to announce that it has published a corporate presentation with respect to the proposed acquisition of Oncogeni Limited and the proposed Placing, as announced by the Company on 22 June 2022.  A copy of the presentation is available on the Company’s website at https://www.roquefortplc.com/category/presentations/

https://www.londonstockexchange.com/news-article/ROQ/update-on-acquisition-of-oncogeni-and-placing/15507863

​

OPEN AN ACCOUNT

If you are interested in opening an account with Optiva Securities, please fill in the details on the apply button.

APPLY NOW

CLIENT AREA

Please ensure that the information you entered is accurate, and that your “Caps Lock” key is set correctly.

LOGIN

Submit a Comment

Optiva Securities Ltd
7 Harp Lane
London EC3R 7DP

Tel +44 (0)20 3137 1902
info@optivasecurities.com
 optivasecurities
@optivalondon
Optiva Securities

KEEP UPDATED

Register to stay updated with the latest news.

    We would like to send you occasional emails about our services and keep you up to date with the latest announcements and news. To join our mailing list, simply click below. You can unsubscribe at any time.

    Optiva Securities Limited is authorised and regulated by the United Kingdom Financial Conduct Authority and are Members of the London Stock Exchange.

    © Copyright Optiva Securities Limited. Registered in England number 3068464
    Share This